A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.
A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.
复制标题
DOI：
10.1007/s11671-009-9431-6
复制
发表时间：
2009-09-16
影响因子：
--
通讯作者：
Huang L
中科院分区：
文献类型：
--
作者：
Mei L;Zhang Y;Zheng Y;Tian G;Song C;Yang D;Chen H;Sun H;Tian Y;Liu K;Li Z;Huang L
肿瘤细胞的多药耐药（MDR）是许多癌症化疗成功的重要障碍。本研究旨在探讨紫杉醇聚己内酯/普朗尼克F68（PCL/Pluronic F68）纳米粒对耐紫杉醇的人乳腺癌细胞耐药的抑制作用。采用改进的溶剂置换法分别以商品化聚己内酯（PCL）和自行合成的聚己内酯/普朗尼克F68（PCL/Pluronic F68）为载体制备多西他赛纳米粒。PCL/Pluronic F68纳米颗粒被发现是具有粗糙和多孔表面的球形形状。纳米颗粒的平均尺寸为约200 nm，具有窄的尺寸分布。两种纳米颗粒制剂的体外药物释放曲线均显示出双相释放模式。与PCL纳米颗粒相比，PCL/Pluronic F68纳米颗粒在紫杉醇耐药的人乳腺癌细胞系MCF-7 TAX 30中的摄取水平增加。在MCF-7 TAX 30细胞培养物中，PCL纳米颗粒的细胞毒性高于商业泰索帝®，但差异不显著（p > 0.05）。然而，PCL/Pluronic F68纳米颗粒实现了比PCL纳米颗粒和Taxotere®两者显著更高水平的细胞毒性（p < 0.05），表明负载紫杉醇的PCL/Pluronic F68纳米颗粒可以克服人乳腺癌细胞中的多药耐药性，因此具有相当大的治疗乳腺癌的潜力。
Multidrug resistance (MDR) in tumor cells is a significant obstacle to the success of chemotherapy in many cancers. The purpose of this research is to test the possibility of docetaxel-loaded poly (ε-caprolactone)/Pluronic F68 (PCL/Pluronic F68) nanoparticles to overcome MDR in docetaxel-resistance human breast cancer cell line. Docetaxel-loaded nanoparticles were prepared by modified solvent displacement method using commercial PCL and self-synthesized PCL/Pluronic F68, respectively. PCL/Pluronic F68 nanoparticles were found to be of spherical shape with a rough and porous surface. The nanoparticles had an average size of around 200 nm with a narrow size distribution. The in vitro drug release profile of both nanoparticle formulations showed a biphasic release pattern. There was an increased level of uptake of PCL/Pluronic F68 nanoparticles in docetaxel-resistance human breast cancer cell line, MCF-7 TAX30, when compared with PCL nanoparticles. The cytotoxicity of PCL nanoparticles was higher than commercial Taxotere®in the MCF-7 TAX30 cell culture, but the differences were not significant (p > 0.05). However, the PCL/Pluronic F68 nanoparticles achieved significantly higher level of cytotoxicity than both of PCL nanoparticles and Taxotere®(p < 0.05), indicating docetaxel-loaded PCL/Pluronic F68 nanoparticles could overcome multidrug resistance in human breast cancer cells and therefore have considerable potential for treatment of breast cancer.
登录
查看更多内容
影响因子：
3.7
作者：
Desai, MP;Labhasetwar, V;Amidon, GL
通讯作者：
Amidon, GL
影响因子：
3.7
作者：
Qaddoumi, MG;Ueda, H;Lee, VHL
通讯作者：
Lee, VHL
影响因子：
14
作者：
Quaglia, Fabiana;Ostacolo, Luisanna;Sciortino, Maria T.
通讯作者：
Sciortino, Maria T.
影响因子：
3.4
作者：
Reich, G
通讯作者：
Reich, G
影响因子：
14
作者：
Cheng, Jianjun;Teply, Benjamin A.;Farokhzad, Omid C.
通讯作者：
Farokhzad, Omid C.